DHRDANAHER CORP /DE/

NYSE danaher.com


$ 251.79 $ -1.83 (-0.72 %)    

Thursday, 27-Jun-2024 15:59:55 EDT
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 251.76
$ 252.67
$ 0.00 x 0
$ 0.00 x 0
$ 251.04 - $ 253.06
$ 181.70 - $ 269.11
2,402,833
na
188.47B
$ 0.88
$ 42.81
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-22-2024 03-29-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 10-23-2023 09-29-2023 10-Q
4 07-24-2023 06-30-2023 10-Q
5 04-25-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 10-19-2022 09-30-2022 10-Q
8 07-20-2022 07-01-2022 10-Q
9 04-20-2022 04-01-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-20-2021 10-01-2021 10-Q
12 07-21-2021 07-02-2021 10-Q
13 04-22-2021 04-02-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 10-22-2020 10-02-2020 10-Q
16 07-23-2020 07-03-2020 10-Q
17 05-06-2020 04-03-2020 10-Q
18 02-21-2020 12-31-2019 10-K
19 10-24-2019 09-27-2019 10-Q
20 07-18-2019 06-28-2019 10-Q
21 04-18-2019 03-29-2019 10-Q
22 02-21-2019 12-31-2018 10-K
23 10-18-2018 09-28-2018 10-Q
24 07-19-2018 06-29-2018 10-Q
25 04-19-2018 03-30-2018 10-Q
26 02-21-2018 12-31-2017 10-K
27 10-19-2017 09-29-2017 10-Q
28 07-20-2017 06-30-2017 10-Q
29 04-20-2017 03-31-2017 10-Q
30 02-22-2017 12-31-2016 10-K
31 10-20-2016 09-30-2016 10-Q
32 07-25-2016 07-01-2016 10-Q
33 04-21-2016 04-01-2016 10-Q
34 02-24-2016 12-31-2015 10-K
35 10-22-2015 10-02-2015 10-Q
36 07-23-2015 07-03-2015 10-Q
37 04-23-2015 04-03-2015 10-Q
38 02-25-2015 12-31-2014 10-K
39 10-16-2014 09-26-2014 10-Q
40 07-17-2014 06-27-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-grants-marketing-authorization-to-cepheid-for-xpert-hcv-test-and-genexpert-xpress-system-first-point-of-care-hepatitis-c-test

https://www.prnewswire.com/news-releases/fda-permits-marketing-of-first-point-of-care-hepatitis-c-rna-test-302185013.html

 danaher-launches-collaboration-with-johns-hopkins-university-aiming-to-improve-neurological-diagnosis

The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisel...

 citigroup-maintains-buy-on-danaher-raises-price-target-to-290

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $280 to $290.

 td-cowen-maintains-buy-on-danaher-raises-price-target-to-290

TD Cowen analyst Dan Brennan maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $280 to $290.

 b-of-a-securities-maintains-neutral-on-danaher-raises-price-target-to-270

B of A Securities analyst Derik De Bruin maintains Danaher (NYSE:DHR) with a Neutral and raises the price target from $258 t...

 barclays-maintains-equal-weight-on-danaher-raises-price-target-to-270

Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Equal-Weight and raises the price target from $260 to $270.